Finance

Lists
Portfolios
Track your investments in one place, get AI insights, and more
Top movers in your lists
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXE
Energy
SIXE
Energy
SIXE
-2.11%
1,205.14
-26.00
-2.11%
1,231.141,233.921,237.061,203.47
SIXV
Health care
SIXV
Health care
SIXV
+1.34%
1,658.73
+21.88
+1.34%
1,636.851,635.521,670.051,635.52
SIXB
Materials
SIXB
Materials
SIXB
+1.20%
1,118.45
+13.30
+1.20%
1,105.151,112.561,125.111,112.56
SIXC
Communications
SIXC
Communications
SIXC
-1.05%
579.08
-6.14
-1.05%
585.22585.22589.50574.23
SIXU
Utilities
SIXU
Utilities
SIXU
-1.01%
883.81
-8.98
-1.01%
892.79892.85892.86876.43
US market summary
The Dow Jones Industrial Average achieved its third consecutive record close and extended its winning streak to five sessions, gaining 0.5%. Conversely, the S&P 500 and the Nasdaq Composite snapped four-day win streaks, declining 0.2% and 0.8% respectively. This divergence occurred as morning rallies in major technology sectors lost steam later in the day.
Dive deeper with AI
SpaceX experiences post-earnings slump on massive artificial intelligence expenditures
Shares of SpaceX fell nearly 14% following the publication of its first quarterly earnings report as a public company. Despite beating revenue expectations and narrowing its losses, the company spooked investors by posting $18.4 billion in capital expenditures. More than 80% of these massive outlays were allocated toward developing AI compute infrastructure.
Dive deeper with AI
Geopolitical optimism stabilizes crude markets near multi-week lows
International benchmark Brent crude oil prices held steady at around $79 per barrel following recent sharp declines. Market sentiment was buoyed by optimistic statements from Washington regarding a potential diplomatic agreement with Iran. Negotiators are aiming to secure a deal that would reopen the strategically critical Strait of Hormuz to normalize shipping traffic.
Dive deeper with AI
Corporate earnings spotlight distinct trajectories for pharmaceutical leaders
Eli Lilly saw strong momentum driven by robust global demand for its diabetes and obesity treatments, which significantly surpassed consensus expectations. Meanwhile, its primary European competitor, Novo Nordisk, experienced a stock decline. Despite an overall quarterly earnings beat, the company faced disappointing sales for its weight-loss pill and produced mixed clinical trial data for its next-generation pipeline.
Dive deeper with AI
AI content may include mistakes. Learn more

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
Google apps